Ignite Creation Date:
2024-05-06 @ 6:30 PM
Last Modification Date:
2024-10-26 @ 2:49 PM
Study NCT ID:
NCT05689853
Status:
RECRUITING
Last Update Posted:
2023-04-20
First Post:
2023-01-10
Brief Title:
Study of AK119 Combined With AK112 in Patients With Advanced Solid Tumors
Sponsor:
Akeso
Organization:
Akeso
Study Overview
Official Title:
An Open-label Multicenter Phase IbII Study to Evaluate the Safety Tolerability and Antitumor Activity of AK119 in Combination With AK112 in Patients With Advanced Solid Tumors
Status:
RECRUITING
Status Verified Date:
2023-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a Phase IbII study to assess the safety tolerability and preliminary efficacy of AK119 combined with AK112 in patients with advanced solid tumors
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None